Europe Pericardium Diseases Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Nonsteroidal Anti-Inflammatory Drugs, Colchicine, IL-1β Inhibitors, Corticosteroids, Immunosuppressants and Others), By Type (Recurrent Pericarditis, Acute Pericarditis, Constrictive Pericarditis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Europe Pericardium Diseases Market Insights, Industry Trends, Forecast to 2035

Europe Pericardium Diseases Market Insights Forecasts to 2035

• The Europe Pericardium Diseases Market Size Was Estimated at USD 881.3 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 6.5% from 2025 to 2035
• The Europe Pericardium Diseases Market Size is Expected to Reach USD 1762.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Europe Pericardium Diseases Market size is anticipated to reach USD 1762.5 Million by 2035, growing at a CAGR of 6.5% from 2025 to 2035. The market is driven by the rising occurrence of heart diseases, growing elderly demographics, and state-of-the-art diagnostic techniques are primary factors leading the way for the availability of medicines that specifically address the disorders of the pericardium, like pericarditis, pericardial effusion, and constrictive pericarditis.

Market Overview

The pericardium diseases market embraces treatment according to the guidelines, mainly with the use of anti-inflammatory agents, and selective use of immunomodulatory drugs. The advanced infrastructure of cardiology ensures high diagnostic accuracy and timely procedural intervention. The tertiary cardiac centers are evaluating the biologicals, which are the recurrent and complicated cases that are referred to. The German pericardium diseases market is characterised by the high diagnostic capability and strong procedural base, which together make significant volumes of pericardial interventions. The cardiothoracic surgery centers carry out the management of constrictive and malignant effusions, thus maintaining the demand for devices.

In October 2025, Novavax is still fulfilling its part of the agreement with Sanofi and has successfully transferred the EU marketing authorization of Nuvaxovid, which has resulted in a payment of $25 million being made as a milestone.

In 2023, Cardiol Therapeutics Inc., a life sciences company in the clinical-stage that is focused on the development and research of anti-inflammatory and anti-fibrotic therapies for heart diseases, announced that all the appointed research centers that are collaborating with the company have been set up and are ready to recruit new patients for the clinical trial ARCHER. The trial is designed to evaluate not only the safety and tolerability of CardiolRx but also its impact on the heart muscle healing process in patients suffering from acute myocarditis.

The new ESC Guidelines have been developed to enhance the diagnosis and treatment of myocarditis and pericarditis. A novel biologic treatment for recurrent pericarditis obtained remarkable commercial success in the first half of 2025, which resulted in the initiation of new studies aimed at patient compliance improvement by changing the dosage from weekly to monthly.

Report Coverage

This research report categorizes the market for the Europe pericardium diseases market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe pericardium diseases market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe pericardium diseases market.

Driving Factors

The pericardium diseases market in Europe is driven by technological advancements in medical equipment and diagnostic devices are greatly impacting the market. The development of new imaging modalities like echocardiography and MRI has made pericardial diseases more accurately diagnosed. The boosting of consultation and diagnostic practices for pericardium diseases among the public and medical professionals. The number of patients with pericardium diseases is on the rise. Infrastructures for healthcare in the developing countries are slowly getting better because of the funds that both the government and the private sector are now directing into them.

Restraining Factors

The pericardium diseases market in Europe is restrained by pericarditis is a condition that frequently remains undiagnosed or misdiagnosed, mainly in outpatient facilities, its lack of distinct symptoms and absence of regular screening protocols. The adoption of new therapies, like targeted biologics, with their exorbitant prices, can be quite a problem for the market, and strong clinical data are necessary to get positive reimbursement rulings in the case of European healthcare systems.

Market Segmentation

The Europe pericardium diseases market share is categorised into drug class, type and distribution channel.

• The nonsteroidal anti-inflammatory drugs segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Europe pericardium diseases market is segmented by drug class into nonsteroidal anti-inflammatory drugs, colchicine, IL-1β inhibitors, corticosteroids, immunosuppressants and others. Among these, the nonsteroidal anti-inflammatory drugs segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by non-steroidal anti-inflammatory drugs (NSAIDs) have become the standard treatment for idiopathic pericarditis (IP) and are widely used. These drugs not only lower the body temperature but also relieve pain and prevent the formation of blood clots and inflammation.

• The acute pericarditis segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on type, the Europe pericardium diseases market is segmented into recurrent pericarditis, acute pericarditis, constrictive pericarditis. Among these, the acute pericarditis segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is driven by the increasing incidence of heart diseases and the awareness of early diagnosis and treatment methods. Hospitalizations happen in about 3.32 cases per 100,000 person-years, which is only 0.2% of total hospital admissions.

• The pharmacies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Europe pericardium diseases market is segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies. Among these, the pharmacies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by advanced therapeutics and optimal treatment protocols within healthcare facilities as the means to manage pericarditis. Patients with acute or recurrent pericarditis usually visit hospitals first, so it is essential to have at hand the anti-inflammatory drugs, corticosteroids, and biologics, such as interleukin-1 inhibitors, available.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe pericardium diseases market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies                                                                                               

• Swedish Orphan Biovitrum
• Sanofi SA
• Novartis AG ADR
• Kiniksa
• Regeneron
• Novartis
• Sanofi
• AstraZeneca
• Pfizer
• Takeda
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In February 2025, Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company developing and commercialising novel therapies for diseases with unmet need, with a focus on cardiovascular indications, announced the development program for KPL-387 in recurrent pericarditis and provided an update on its corporate strategy.

Market Segment

This study forecasts revenue at the Europe, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Europe Pericardium Diseases Market based on the below-mentioned segments:

Europe Pericardium Diseases Market, By Drug Class

• Nonsteroidal Anti-Inflammatory Drugs
• Colchicine
• IL-1β Inhibitors
• Corticosteroids
• Immunosuppressants
• Others

Europe Pericardium Diseases Market, By Type

• Recurrent Pericarditis
• Acute Pericarditis
• Constrictive Pericarditis

Europe Pericardium Diseases Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies